International Social-Impact Award Contender: TGen's Social Media Analysis Project on platform.org
In a significant stride towards understanding Alzheimer's disease, the Translational Genomics Research Institute (TGen) has developed an innovative web-based scientific study called "our platform". This groundbreaking project, led by Dr. Huentelman, an Associate Professor in TGen's Neurogenomics Division, aims to shed light on the intricacies of brain learning and memory processes with the ultimate goal of developing a better-informed cure for Alzheimer's.
Our platform is an AI-based genetic analysis platform that utilises de-identified whole genome sequences from Alzheimer's patients and healthy controls. By leveraging machine learning systems, it stratifies genomes and uncovers causal genes while avoiding spurious results due to genetic background differences. This approach, validated in research on Amyotrophic Lateral Sclerosis (ALS), not only rediscovers known disease genes but also helps identify new genetic targets, demonstrating its potential utility for Alzheimer's research.
The platform's primary objective is to uncover new genetic contributors to Alzheimer's, thereby facilitating a deeper understanding of the disease's mechanisms and aiding in the development of targeted therapies. The project has already garnered the attention of nearly 28,000 volunteers, with researchers aiming to gather results from as many as 1 million participants.
TGen, based in Phoenix, Arizona, is a non-profit organisation dedicated to conducting groundbreaking research with life-changing results, particularly in cancer, neurological disorders, and diabetes. The institute's work focuses on the translational research process, which aims to rapidly move research towards patient benefit. TGen collaborates with scientists and medical professionals worldwide to contribute to patient care through the efficiency and effectiveness of the translational process.
The Translational Genomics Research Institute's (TGen) social-media investigation of Alzheimer's disease, called our platform.org, has been recognised as a finalist in the prestigious CLASSY Awards. This annual event, the largest social impact awards ceremony in the United States, brings together top leaders from the social sector to collaborate on solving social problems. The 5th annual CLASSY Awards will be held on May 3, 2014, at the Marriott Marquis in San Diego.
Alzheimer's disease is a significant socioeconomic issue, with more than 5 million Americans living with the disease, it being the 6th leading cause of death in the U.S., and costing the nation more than $200 billion to treat annually. For more information about TGen and their ongoing research, visit www.tgen.org.
Steve Yozwiak, TGen's Senior Science Writer, can be contacted at [email protected] or 602-343-8704 for further details about "our platform" and its contributions to Alzheimer's disease research.
[1] Source: [Link to the original research paper or press release] [2] Source: [Link to another relevant research paper or news article] [3] Source: [Link to another relevant research paper or news article] [4] Source: [Link to another relevant research paper or news article]
- The field of neurogenomics, a critical component of science, is advancing rapidly, as evidenced by the Translational Genomics Research Institute's (TGen) innovative web-based study called "our platform".
- This study, led by Dr. Huentelman, an Associate Professor in TGen's Neurogenomics Division, is focused on the intricacies of brain learning and memory processes, with the ultimate goal of developing a better-informed cure for Alzheimer's.
- Our platform is an AI-based genetic analysis platform that uses de-identified whole genome sequences from Alzheimer's patients and healthy controls.
- By leveraging machine learning systems, it stratifies genomes and uncovers causal genes while avoiding spurious results due to genetic background differences.
- This approach, validated in research on Amyotrophic Lateral Sclerosis (ALS), not only rediscovers known disease genes but also helps identify new genetic targets.
- The platform's primary objective is to uncover new genetic contributors to Alzheimer's, thereby facilitating a deeper understanding of the disease's mechanisms and aiding in the development of targeted therapies.
- The project has already garnered the attention of nearly 28,000 volunteers, with researchers aiming to gather results from as many as 1 million participants.
- TGen, based in Phoenix, Arizona, is a non-profit organisation dedicated to conducting groundbreaking research with life-changing results, particularly in cancer, neurological disorders, and diabetes.
- The institute's work focuses on the translational research process, which aims to rapidly move research towards patient benefit.
- TGen collaborates with scientists and medical professionals worldwide to contribute to patient care through the efficiency and effectiveness of the translational process.
- The Translational Genomics Research Institute's (TGen) social-media investigation of Alzheimer's disease, called our platform.org, has been recognised as a finalist in the prestigious CLASSY Awards.
- These awards, the largest social impact awards ceremony in the United States, bring together top leaders from the social sector to collaborate on solving social problems.
- The 5th annual CLASSY Awards will be held on May 3, 2014, at the Marriott Marquis in San Diego.
- Alzheimer's disease is a significant socioeconomic issue, with more than 5 million Americans living with the disease.
- It is the 6th leading cause of death in the U.S., and costing the nation more than $200 billion to treat annually.
- Source: [Link to the original research paper or press release]
- Source: [Link to another relevant research paper or news article]
- Source: [Link to another relevant research paper or news article]
- Source: [Link to another relevant research paper or news article]
- For more information about TGen and their ongoing research, visit www.tgen.org.
- Steve Yozwiak, TGen's Senior Science Writer, can be contacted at [email protected] or 602-343-8704 for further details about "our platform" and its contributions to Alzheimer's disease research.
- The study of sleep, a crucial aspect of health and wellness, has links to our platform's research in Alzheimer's disease.
- Workplace-wellness programs, focused on promoting fitness and exercise, can help in managing chronic diseases, including Alzheimer's.
- Medical-conditions like diabetes and cardiovascular health are also relevant to Alzheimer's, as they increase the risk of developing the disease.
- Respiratory conditions, digestive health, eye-health, hearing, and skin-care are other aspects of health that can be influenced by our lifestyle choices.
- Mental-health, a crucial aspect of health-and-wellness, is linked to neurogenomics research, as it involves the brain's functions and genetic makeup.
- Mens-health, women's-health, parenting, and weight-management are essential topics in health discussions, particularly in the context of chronic diseases and aging.
- In the same vein, nutrition, climate-change, autoimmune-disorders, cancers, and neurological-disorders are all areas that intersect with the health sphere, requiring attention from environmental-science, finance, and even fashion-and-beauty industries.
